By Colin KellaherShares of Seagen Inc. rose 5% in premarket trading Thursday after The Wall Street Journal reported that Merck & Co. is closing in on a takeover of the biotechnology company in a deal that could be worth $40 billion or more. The Journal, which last month reported that Merck was circling Seagen, said the companies are discussing a purchase price topping $200 a share.

Source: Wall Street Journal July 07, 2022 20:37 UTC